Amrutanjan Health Care Limited · NSE:AMRUTANJAN
Amrutanjan Health Care — Q2 FY23 Earnings Presentation
18 slides from Amrutanjan Health Care's earnings presentation, Nov 5, 2022
Slide 1: Exchange filing cover letter
AHCL/ SE/ 34/2022-23 November 05 2022 The National Stock Exchange of India Limited BSE Limited "Exchange Plaza", C-1, Block G Department of Corporate Services Bandra-Kurla Complex, Sandra (E) 1st Floor, Mumbai 400 051 P.J. Towers, Dalal Street, !SIN : INE098F0 1031 Mumba i 400 001 Symbol: AMRUTANJAN
Slide 2: Investor Presentation Quarter & Half Year Ended 30th September 2022
Amrutanjan Health Care Limited Investor Presentation Quarter & Half Year Ended 30th September 2022 Date: 4th November 2022
Slide 3: Contents
Contents [ a. Business Update ] [ b. H1 FY23 Performance ] [ c. Q2 FY23 Performance ] [ d. Way Forward ] Investor Presentation | Quarter and Half Year Ended 30th September 2022 2
Slide 4: Business Update
Business Update Investor Presentation | Quarter and Half Year Ended 30th September 2022 3
Slide 5: Business Update
Business Update A. We continue to see slowdown in the pain category which according to Kantar has slowed down by 17% . B. We have had a one time event in the sales system that is being corrected which has caused coverage and secondary sales disturbance. We ask investors to treat the softness and con
Slide 6: Comfy New Products
Business Update (.-------- “Comfy” New Products ] Period Cup Tampons ------ XL Value Pack ;t~~1~z:1 ,W(((i!/1 } -- ~ Investor Presentation | Quarter and Half Year Ended 30th September 2022 5
Slide 7: H1 FY23 Performance
H1 FY23 Performance Investor Presentation | Quarter and Half Year Ended 30th September 2022 6
Slide 8: Financials – H1 FY23
Financials – H1 FY23 (Rs. in Crores) Gross Sales Profit Before Tax Profit After Tax 202.06 208.50 31.91 42.64 22.67 16.43 H1 FY23 H1 FY22 H1 FY23 H1 FY22 H1 FY23 H1 FY22 Investor Presentation | Quarter and Half Year Ended 30th September 2022 7
Slide 9: Financials – H1 FY23: reasons for reduction in Profit Before Tax
Financials – H1 FY23 (Rs. in Crores) Major reasons for reduction in Profit Before Tax (H1 FY23 vs H1 FY22): Particulars Amount Remarks Top Line reduction: Key Product 8 ML balm sales has come down by 17.49 crs Product Mix: Comfy Sales has grown by 8.45 crs Decrease in Gross Margin due to top line Ra
Slide 10: Expenses – H1 FY23
Expenses – H1 FY23 (Rs. in Crores) Employee Benefit Expenses 24.42 24.33 H1 FY23 H1 FY22 Increase: 0.37% Advertisement & Selling Expenses Other Expenses 25.57 26.75 23.49 16.41 H1 FY23 H1 FY22 H1 FY23 H1 FY22 Decrease: 4.41% Increase: 43.14% Investor Presentation | Quarter and Half Year Ended 30th S
Slide 11: Financials – H1 FY23 – OTC Division
Financials – H1 FY23 – OTC Division (Rs. in Crores) Gross Sales - OTC 184.60 189.61 Notes: • Key raw material prices (excluding Menthol crystal price) are higher H1 FY23 H1 FY22 when compared to H1 FY22. • The prices of packing materials are Gross Sales - Comfy higher when compared to H1 FY22. 41.13
Slide 12: Financials – H1 FY23 – Beverage Division
Financials – H1 FY23 – Beverage Division (Rs. in Crores) Gross Sales - Beverages 18.16 16.39 Notes: • Raw Material & Packing Material prices are higher when compared to H1 FY23 H1 FY22 H1 FY22. • Advertisement spend is at Rs. 3.10 Gross Sales - Electro Plus cr for H1 FY23 against Rs. 2.48 cr for 12.
Slide 13: Q2 FY23 Performance
Q2 FY23 Performance Investor Presentation | Quarter and Half Year Ended 30th September 2022 12
Slide 14: Financials – Q2 FY23
Financials – Q2 FY23 (Rs. in Crores) Gross Sales Profit Before Tax Profit After Tax 123.40 121.61 26.36 19.85 17.42 12.77 Q2 FY23 Q2 FY22 Q2 FY23 Q2 FY22 Q2 FY23 Q2 FY22 Growth:1.47% Investor Presentation | Quarter and Half Year Ended 30th September 2022 13
Slide 15: Financials – Q2 FY23
Financials – Q2 FY23 (Rs. in Crores) Gross Sales - OTC Gross Sales - Beverages 7.17 115.76 115.02 6.14 Q2 FY23 Q2 FY22 Q2 FY23 Q2 FY22 Growth: 0.64% Growth: 16.78% Gross Sales - Comfy Gross Sales - Electro Plus 5.57 24.27 4.65 21.51 Q2 FY23 Q2 FY22 Q2 FY23 Q2 FY22 Growth: 12.83% Growth: 19.78% Inves
Slide 16: Way Forward
Way Forward Investor Presentation | Quarter and Half Year Ended 30th September 2022 15
Slide 17: Way Forward
Way Forward We remain focused on executing our key priorities: • Expand distribution • Go global • Grow E-Commerce vertical • Costs control Investor Presentation | Quarter and Half Year Ended 30th September 2022 16
Slide 18: Investor Presentation | Quarter and Half Year Ended 30th September 2022
Investor Presentation | Quarter and Half Year Ended 30th September 2022 17
Amrutanjan Health Care — Q2 FY23 Earnings Presentation on 6ix